P21 overexpressing immune cells with an antigen-binding domain at their surface

Abstract

The present invention concerns genetically modified immune cell, which (a) overexpresses p21 compared to a corresponding non-genetically modified immune cell, (b) expresses at its surface a recombinant antigen binding domain, and (c) is a monocyte, a macrophage, or a dendritic cell, as well as methods for producing them, pharmaceutical compositions comprising them, and their use as a medicament, in particular in the treatment of a subject suffering from a cell proliferative disorder, in particular cancer.